Orange Book product · Brand (NDA)
ROZLYTREK
ENTRECTINIB
At a glance
Aug 15, 2019
Approved
Brand (NDA)
Application
Not listed
TE code
19
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Aug 15, 2019
6 yr 11 mo ago
Today
Exclusivity ends · ODE-265
Orphan-drug exclusivity (7 years)
Aug 15, 2026
in 2 mo
Exclusivity ends · ODE-313
Orphan-drug exclusivity (7 years)
Aug 15, 2026
in 2 mo
Exclusivity ends · NPP
New patient population exclusivity (3 years)
Oct 20, 2026
in 4 mo
Patent 8673893 expires
Listed method-of-use patent (U-2618) expiration.
Jul 08, 2028
in 2 yr 1 mo
Patent 8673893 expires
Listed method-of-use patent (U-2617) expiration.
Jul 08, 2028
in 2 yr 1 mo
Patent 9029356 expires
Listed drug substance patent expiration.
Jul 08, 2028
in 2 yr 1 mo
Patent 9085558 expires
Listed drug product patent expiration.
Jul 08, 2028
in 2 yr 1 mo
Patent 9255087 expires
Listed method-of-use patent (U-2618) expiration.
Jul 08, 2028
in 2 yr 1 mo
Patent 9255087 expires
Listed method-of-use patent (U-2617) expiration.
Jul 08, 2028
in 2 yr 1 mo
Patent 9616059 expires
Listed method-of-use patent (U-2618) expiration.
Jul 08, 2028
in 2 yr 1 mo
Exclusivity ends · ODE-448
Orphan-drug exclusivity (7 years)
Oct 20, 2030
in 4 yr 5 mo
Patent 8299057 expires
Listed drug substance patent expiration.
Mar 10, 2032
in 5 yr 10 mo
Patent 9085565 expires
Listed drug substance patent expiration.
May 22, 2033
in 7 yr
Patent 9649306 expires
Listed method-of-use patent (U-2618) expiration.
May 22, 2033
in 7 yr
Patent 9649306 expires
Listed method-of-use patent (U-2617) expiration.
May 22, 2033
in 7 yr
Patent 10231965 expires
Listed method-of-use patent (U-2618) expiration.
Feb 17, 2035
in 8 yr 10 mo
Patent 10231965 expires
Listed method-of-use patent (U-2617) expiration.
Feb 17, 2035
in 8 yr 10 mo
Patent 10561651 expires
Listed method-of-use patent (U-2745) expiration.
Feb 19, 2035
in 8 yr 10 mo
Patent 10738037 expires
Listed drug substance patent expiration.
May 18, 2037
in 11 yr 1 mo
Patent 11091469 expires
Listed method-of-use patent (U-2617) expiration.
May 18, 2037
in 11 yr 1 mo
Patent 11091469 expires
Listed method-of-use patent (U-2618) expiration.
May 18, 2037
in 11 yr 1 mo
Patent 10398693 expires
Listed drug product patent expiration.
Jul 18, 2038
in 12 yr 3 mo
Patent 11253515 expires
Listed drug product patent expiration.
Jul 18, 2038
in 12 yr 3 mo
Pharmaceutical detail
Active ingredient
ENTRECTINIB
Strength
200MG
Dosage form
CAPSULE
Route
ORAL
TE code
Not listed
Application
NDA 212725
Product number
002
Marketing status
RX
Reference listed drug (RLD)
Yes
Reference standard (RS)
Yes
Active-ingredient family
View full familyThis is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.
Marketing exclusivity (4)
- ODE-265Orphan-drug exclusivity (7 years)
Aug 15, 2026
in 2 mo
- ODE-313Orphan-drug exclusivity (7 years)
Aug 15, 2026
in 2 mo
- NPPNew patient population exclusivity (3 years)
Oct 20, 2026
in 4 mo
- ODE-448Orphan-drug exclusivity (7 years)
Oct 20, 2030
in 4 yr 5 mo
Listed patents (19)
| Patent | Expires | In | Type |
|---|---|---|---|
| 8673893 | Jul 08, 2028 | in 2 yr 1 mo | U-2618 |
| 8673893 | Jul 08, 2028 | in 2 yr 1 mo | U-2617 |
| 9029356 | Jul 08, 2028 | in 2 yr 1 mo | SubstanceProduct |
| 9085558 | Jul 08, 2028 | in 2 yr 1 mo | Product |
| 9255087 | Jul 08, 2028 | in 2 yr 1 mo | U-2618 |
| 9255087 | Jul 08, 2028 | in 2 yr 1 mo | U-2617 |
| 9616059 | Jul 08, 2028 | in 2 yr 1 mo | U-2618 |
| 8299057 | Mar 10, 2032 | in 5 yr 10 mo | SubstanceProduct |
| 9085565 | May 22, 2033 | in 7 yr | SubstanceProduct |
| 9649306 | May 22, 2033 | in 7 yr | U-2618 |
| 9649306 | May 22, 2033 | in 7 yr | U-2617 |
| 10231965 | Feb 17, 2035 | in 8 yr 10 mo | U-2618 |
| 10231965 | Feb 17, 2035 | in 8 yr 10 mo | U-2617 |
| 10561651 | Feb 19, 2035 | in 8 yr 10 mo | U-2745 |
| 10738037 | May 18, 2037 | in 11 yr 1 mo | SubstanceProductU-2946 |
| 11091469 | May 18, 2037 | in 11 yr 1 mo | U-2617 |
| 11091469 | May 18, 2037 | in 11 yr 1 mo | U-2618 |
| 10398693 | Jul 18, 2038 | in 12 yr 3 mo | Product |
| 11253515 | Jul 18, 2038 | in 12 yr 3 mo | Product |

